# Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome

> **NCT04355689** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Nacuity Pharmaceuticals, Inc.** · enrollment: 49 (actual)

## Conditions studied

- Usher Syndromes

## Interventions

- **DRUG:** NPI-001
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04355689
- **Lead sponsor:** Nacuity Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-03
- **Primary completion:** 2025-06-20
- **Final completion:** 2026-04
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2025-12-23

## Collaborators

- Foundation Fighting Blindness

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04355689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04355689, "Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04355689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*